Generic Name and Formulations:
Somatropin (rDNA origin) 8.8mg; per vial; lyophilized pwd for SC inj after reconstitution; diluent contains benzyl alcohol.
EMD Serono, Inc.
Indications for ZORBTIVE:
Short bowel syndrome in conjunction with nutritional support (see full labeling).
Rotate inj site. Initially 0.1mg/kg SC inj once daily; max 8mg/day. Treat for 4 weeks. If fluid retention or arthralgia occurs; reduce dose by 50%. Discontinue therapy for up to 5 days if severe toxicities occur; if resolved, resume at 50% of original dose; if unresolved within 5 days or recurs, discontinue permanently.
Active malignancy. Acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure. Active proliferative or severe non-proliferative diabetic retinopathy.
Monitor for potential malignant changes of preexisting nevi. Increased mortality in those with acute critical illness (see Contraindications). Impaired glucose tolerance/diabetes mellitus: monitor blood glucose. Hypoadrenalism: monitor serum cortisol levels. Evaluate thyroid function in those with hypopituitarism before starting and after 4 weeks treatment; correct thyroid function, if needed. Perform funduscopic evaluation for intracranial hypertension at initiation; discontinue if papilledema occurs. Elderly. Pregnancy. Nursing mothers.
May antagonize glucocorticoids. Concomitant antidiabetic treatment may need to be adjusted.
Growth hormone (GH).
Edema (eg, facial, peripheral), arthralgia, inj site pain, flatulence, abdominal pain, vomiting, pain, nausea; hypersensitivity reactions, tissue turgor (swelling in hands/feet), musculoskeletal discomfort, carpal tunnel syndrome (reduce dose or discontinue if unresolved), acute pancreatitis.
Vials—1 (w. diluent)
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States